The NPA is asking for the RPSGB retention fee to be held at the present level, given the financial pressures on pharmacy businesses, many of which pay retention fees for their staff.
Margaret Peycke, NPA External Relations Manager said
“The justification to charge RPSGB members more is unclear, especially as such a large increase in [...]

InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides antidiabetic efficacy consistent with maximal dose thiazolidinedione (TZD) therapy but with less hematocrit reduction and weight gain.
The 4 week double blind placebo controlled [...]